Treatment of Hypoglycemia Following Gastric Bypass Surgery

NCT02527993 on ClinicalTrials.gov · last registry update 2018-03-07

A small phase 4 — 11 participants, against a typical 75. The sponsor logged completion for 8 April 2017. Primary outcome, as filed: Changes in blood glucose (mmol/L) assessed by continuous glucose monitoring (CGM). liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Zealand University Hospital
Sponsor type: Other
Enrollment: 11
Started: 2015-10
Primary completion: 2017-04-08 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Changes in blood glucose (mmol/L) assessed by continuous glucose monitoring (CGM).

Conditions studied

Hypoglycemia · Obesity · Surgery

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.